Day: June 28, 2022

Acquisition of Prima XL will expand Duck Creek’s global footprint across EMEA and APAC

Boston, June 28, 2022 (GLOBE NEWSWIRE) — Duck Creek Technologies (NASDAQ: DCT), the intelligent solutions provider defining the future of property and casualty (P&C) insurance, today announces it has agreed to acquire Prima XL, France-based Prima Solutions’ flagship commercial reinsurance technology solution. Prima XL will further enhance Duck Creek’s value to current and future customers by simplifying reinsurance management. The transaction terms also include an agreement by Duck Creek to purchase Prima Compliance for Solvency II, a compliance solution which Duck Creek intends to continue offering in the French marketplace.

With the proposed acquisition of these two cloud-based, software-as-a-service (SaaS) solutions, Duck Creek will expand its global operations and local presence in the European (EMEA) and Asia-Pacific-Australia (APAC) regions, retaining core talent and operations in Paris, France to complement the company’s existing operations in the United Kingdom and Spain. Upon completion of the proposed transaction, dedicated Prima Solutions’ personnel will join Duck Creek to support Prima XL and Prima Compliance sales, customer success, and operations. The Prima XL reinsurance management solution will be available to insurance organizations operating on Duck Creek systems and systems other than Duck Creek.

Mike Jackowski, Duck Creek’s chief executive officer commented, “The insurance industry is undergoing a generational modernization of its technology infrastructure while organizations seek innovative ways to better manage the entire end-to-end insurance cycle in the cloud. Core systems for policy, rating, billing and claims are advancing at a rapid pace, and Duck Creek is a well-positioned leader here.” Jackowski continued, “In addition to our global core systems vision, by adding Prima XL to our product family, we are focused on accelerating insurance carriers’ technology goals by delivering evergreen, intelligent, cloud-based SaaS solutions that streamline and automate reinsurance operations.”

Julien Victor, CEO of Prima Solutions, would join Duck Creek as managing director, reinsurance management to continue leading the growth and expansion of Prima XL and Prima Compliance under Duck Creek’s stewardship. Victor said, “We are delighted to join the Duck Creek group. Existing and future clients will benefit from the international footprint of a leading insurance software vendor, combined with large and seasoned teams of functional and technical experts. I am convinced that this transaction will increase the leadership positions of Prima XL and Prima Compliance in their respective markets. “

As is customary, the transaction remains subject to the information and consultation processes of the relevant employee representative bodies in accordance with applicable laws.

About Prima XL

Prima XL is a powerful, intuitive, cloud-based reinsurance software that collects, centralizes, and analyzes all data for insurers, reinsurers, and brokers. Prima XL tracks all the information related to reinsurance policies (treaties and facultative policies, claims, incidents, accounting data, technical data, auxiliary data, financial data, and more), allowing insurance businesses to manage all of their policies from underwriting to switch and renewals. Prima XL is a flexible solution tailored to international organizations using multiple currencies and multiple GAAP requirements.

About Prima Compliance

Prima Compliance is a cloud platform for managing regulatory compliance to satisfy Europe’s Solvency II directive. Combining actuarial calculations (Solvency II Pillar 1) and internal regulatory reporting at the national and European levels (Solvency II Pillar 3), Prima Compliance is a secure, all-in-one solution that is always compliant with Solvency II regulations, giving insurance organizations peace of mind when it comes to European regulatory compliance.

About Duck Creek Technologies

Duck Creek Technologies (NASDAQ: DCT) is the intelligent solutions provider defining the future of the property and casualty (P&C) and general insurance industry. We are the platform upon which modern insurance systems are built, enabling the industry to capitalize on the power of the cloud to run agile, intelligent, and evergreen operations. Authenticity, purpose, and transparency are core to Duck Creek, and we believe insurance should be there for individuals and businesses when, where, and how they need it most. Our market-leading solutions are available on a standalone basis or as a full suite, and all are available via Duck Creek OnDemand. Visit www.duckcreek.com to learn more. Follow Duck Creek on our social channels for the latest information – LinkedIn and Twitter.

Carley Bunch
Duck Creek Technologies
+1 201 962 6091
carley.bunch@duckcreek.com

Drake Manning
Duck Creek Technologies
+1 860 877 3609
drake.manning@duckcreek.com

June 28, 2022

Testing in accordance with ISO 18562 and ISO 10993 standards conducted by five certified, independent testing laboratories in the US and Europe

Amsterdam, the Netherlands – On June 14, 2021, Royal Philips’ (NYSE: PHG; AEX: PHIA) subsidiary Philips Respironics, initiated a voluntary recall notification/field safety notice* to address potential health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam in specific CPAP, BiPAP and mechanical ventilator devices.

At the time the recall notification/field safety notice* was issued, Philips Respironics relied on an initial, limited data set and toxicological risk assessment, and assumed a worst-case scenario for the possible health risks out of an abundance of caution. Since then, together with five certified, independent testing laboratories in the US and Europe, as well as other qualified third-party experts, Philips Respironics has been conducting a comprehensive test and research program on the PE-PUR foam to better assess and scope the potential patient health risks related to possible emission of particulates from degraded foam and volatile organic compounds (VOCs).

This update is intended to provide healthcare providers, patients, and other stakeholders with updated information on the testing results to date. Philips will continue to provide regular updates as new test results and assessments become available, as not all tests have been completed to date.

The overall guidance for healthcare providers and patients in the recall notification/field safety notice* remains unchanged at this time.

Testing methods
Testing results and conclusions to date are grouped by device air path design and configuration, i.e., based on how the air flows through the device. Of the five device categories, the first-generation DreamStation devices represent 68% of the registered affected devices globally. Within each device category, testing and analyses are performed on new devices with pristine foam, devices with lab-aged foam and used devices:

• Visual assessment of the foam in returned/used devices to assess the prevalence of visible foam degradation.
• VOC testing to identify and quantify organic compounds that may be inhaled during device use.
• Particulate Matter (PM) testing to determine concentrations of respirable particulates, i.e., particulates up to 10 micrometers in diameter, as it relates to inhalation risks and established health thresholds.
• Additional physical, chemical and biological testing of the PE-PUR foam related to patient risks if patients were in contact with foam material.

The complete update on the PE-PUR testing results and conclusions available to date can be found here, and the main findings have been presented below. Healthcare providers, patients, and other stakeholders should use the complete update for any informed decision making, and not the overview in this press release.

“I deeply regret the concern experienced by patients who rely on the affected Respironics sleep and respiratory devices for their health and quality of life and want to emphasize our commitment to providing them with a resolution as fast as possible,” said Frans van Houten, CEO of Royal Philips. “More than 1,000 of our colleagues are working extremely hard to achieve this. While certain prolonged tests across the affected product categories are still to be completed, the results to date for the first-generation DreamStation devices, which represent the majority of the registered affected devices, show a very low prevalence of visible foam degradation. In addition, the new and used first-generation DreamStation devices passed volatile organic compound and respirable particulate emission testing. This is very encouraging. Results to date also indicate that ozone cleaning significantly exacerbates foam degradation.”

First-generation DreamStation devices (68% of registered affected devices globally)
Visual assessment: In order to determine the prevalence of foam degradation, which may result in foam particulate emission, a visual assessment of the foam was performed on a sample of 60,847 returned/used first-generation DreamStation devices from the US and Canada. The visual inspection was conducted according to a specific protocol as part of the repair process. The sample included 36,341 devices for which the users reported no use of ozone cleaning, 11,309 devices for which the users reported use of ozone cleaning, and 13,197 devices for which it was reported unknown by the user whether ozone cleaning was used.

• Prevalence of visible foam degradation (US and CA): 164 of 36,341 (0.5%) devices with self-reported no ozone use showed significant visible foam degradation.
• Impact of repeated ozone cleaning: Devices with self-reported ozone use were 14x more likely to have significant visible foam degradation than those with self-reported no ozone use: 777 of 11,309 devices (7%) showed significant visible foam degradation.
• Assessment of a sample of devices linked to reported alleged foam degradation complaints: 422 devices of the inspected 60,847 returned/used devices are linked to a reported foam degradation complaint. However, only 18 out of these 422 devices (4%) actually showed visible foam degradation.

In those devices where visible foam degradation was significant, i.e., there was reduction in foam volume, it was observed that there was accumulation of degraded foam within the airpath inside the device. The foam becomes hygroscopic (i.e., absorbs moisture) and sticky with degradation. It also loses significant volume and increases density as the structure changes from a foam to a viscous liquid material. As such, even when foam particulates are formed by degradation, they are likely to accumulate within the device and may not be directly emitted by the device.

A visual assessment of the foam was also performed on a sample of 1,360 returned/used first-generation DreamStation devices from various countries in Europe and on a sample of 931 returned/used devices from Japan.

• Prevalence of visible foam degradation (EU and JPN): None of the assessed devices from Europe or Japan showed significant visible degradation.

Volatile Organic Compounds (VOCs): VOC testing according to ISO 18562-3 was performed on new, lab-aged and used devices to (1) quantify VOC emissions from devices, and (2) assess the toxicological risk associated with exposure to the quantified concentrations of those VOCs. It is important to note that these tested new and lab aged first-generation DreamStation devices were not exposed to ozone cleaning, in accordance with the instructions for use.

• As previously provided in an update on December 23, 2021, VOC emissions are below established limits based on ISO 18562-3 testing and evaluation of new, lab-aged, and used devices. Exposure to the level of VOCs identified to date for the first-generation DreamStation devices is not anticipated to result in long-term health consequences for patients.

Particulate Matter (PM): PM testing according to ISO 18562-2 was performed on the devices to (1) quantify the particulate matter emitted from devices, and (2) assess whether the concentration detected is less than thresholds provided in the standard.

• New devices and used devices (including used devices with visible foam degradation) were tested and were all found to be compliant with ISO 18562-2 allowable limits for PM emissions.
• Tested PM emissions of used devices with degradation were not statistically different than PM emissions without degradation, suggesting that degradation did not contribute to appreciable elevated levels of respirable particles in the devices tested.
• The used devices that were tested for PM emissions, were also evaluated for cleanliness based on a visual inspection of the exterior of the device, i.e., the presence of environmental materials on the external surface of the device, such as the inlet filter location. For these devices, average particulate matter counts in devices classified as ‘dirty’ were significantly greater than those classified as ‘clean’.
  

Biocompatibility testing of (degraded) PE-PUR foam: Additional testing is still being performed in accordance with ISO 10993 to facilitate a toxicological risk assessment of (degraded) foam particulates, which is relevant if they would potentially contact the patient. This testing includes chemical characterization (i.e., what chemicals may potentially extract or leach from the foam and have direct contact with body tissues and/or fluids), in vitro assessment (i.e., tests performed in a test tube, dish, etc. outside the body), and in vivo assessment (i.e., preclinical testing) of new, lab aged and/or used PE-PUR foam.

To support the assessment of potential genotoxicity, cytotoxicity, and irritation risks of lab-aged foam, chemical characterization of lab-aged foam, as well as experiments to assess the amount of foam that can potentially contact the patient are being conducted, as lab-aged foam did not pass Ames (genotoxicity), cytotoxicity and skin irritation bioassay testing. Further, complementing the lab-aged foam assessment, a chemical characterization of returned/used degraded foam is also being conducted to better elucidate risks under field conditions. Per ISO 10993, the bioassay results cannot stand alone and, therefore, a positive Ames, cytotoxicity, or skin irritation result triggers a required follow-up evaluation including identification of potential confounding factors, and a weight of evidence assessment to determine a confirmed conclusion on potential risks for patients under expected usage of the device.

Other devices under the recall notification/field safety notice
Other devices that are being tested include DreamStation Go (1% of the registered devices) and SystemOne (26% of the registered devices). These devices each have a different air path design/configuration compared to the first-generation DreamStation devices but contain the same PE-PUR foam.

New DreamStation Go and SystemOne devices passed VOC and PM testing based on standards available prior to ISO 18562 i.e., Indoor Air Quality Evaluation (as previously disclosed in the April 25, 2022, update). Further ISO 18562 VOC and PM testing is ongoing. The results of ISO 10993 biocompatibility testing of degraded PE-PUR foam for the first-generation DreamStation devices, which is ongoing, will also apply to DreamStation Go and SystemOne devices.

Further devices include Trilogy 100/200 (3% of the registered devices) and OmniLab/A-Series BiPAP (2% of the registered devices). New Trilogy 100/200 passed VOC and PM testing. New OmniLab devices passed VOC and PM testing based on standards available prior to ISO 18562 i.e., Indoor Air Quality Evaluation (as previously disclosed in the April 25, 2022, update). New and used OmniLab devices passed VOC testing based on ISO 18562. Further testing is ongoing.

Summary of ongoing tests
The first-generation DreamStation, DreamStation Go and SystemOne CPAP/BiPAP devices represent 95% of the registered affected devices globally. Philips Respironics expects to complete the remaining VOC and PM testing for these devices, as well as the degraded foam toxicological risk assessments (in accordance with ISO 10993) in the coming months. Philips Respironics will also continue with the tests to assess the impact of repeated ozone cleaning on foam degradation in these CPAP/BiPAP devices, as well as the remaining VOC and PM testing and the degraded foam toxicological risk assessments for the Trilogy 100/200 and OmniLab ventilator devices.

Silicone foam testing per FDA’s November 2021 request
In November 2021, the FDA requested that Philips retain an independent laboratory to perform additional testing to determine what, if any, potential safety risks may be posed to patients by silicone-based foam. Philips Respironics engaged independent testing laboratories to perform additional VOC testing. Based on the draft reports, Philips Respironics has not identified any safety issues. The assessment is being completed, and the final reports are subject to FDA review, which are expected in the coming months.

Guidance for healthcare providers and patients
As indicated, this update is intended to provide healthcare providers, patients, and other stakeholders with updated information on the testing results to date. The overall guidance for healthcare providers and patients in the recall notification/field safety notice* remains unchanged at this time. Philips Respironics remains fully committed to addressing all devices affected by the recall notification/field safety notice* and continues to work with the relevant competent authorities to further optimize the remediation plan. To date, approximately 2.7 million replacement devices and repair kits have been produced.

Additional information
Further information, including the complete update and FAQs, as well as video messages from Philips CEO Frans van Houten, Chief Business Leader Connected Care Roy Jakobs and Technical Project Manager for the test and research program Jan Bennik, can be found here and here.

* Voluntary recall notification in the US/field safety notice for the rest of the world.

For media questions, please contact:

Steve Klink
Philips Global Press Office
Tel.: +31 6 10888824
E-mail: steve.klink@philips.com

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 15213446
E-mail: ben.zwirs@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This statement contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Attachment

• Dreamstation 1 device

FCB named 2022 North America Network of the Year and #2 Network Overall

CANNES, France, June 27, 2022 (GLOBE NEWSWIRE) — At the 2022 Cannes Lions International Festival of Creativity, FCB became the first in Cannes Lions history to win the coveted Titanium Lion three years in a row. The prestigious honor, awarded to FCB Inferno for Virgin Group’s “Dyslexic Thinking,” brought the FCB network count to a total of 70 Lions, which included 1 Titanium, 3 Grand Prix, 12 Gold, 26 Silver and 28 Bronze Lions. Early in the week, FCB Health was named Healthcare Network of the Year and AREA 23, an IPG Health Company, was named Healthcare Agency of the Year. On the festival’s final day, FCB was honored as the #2 Network overall in 2022 and the North America Network of the Year for the fourth straight year, and FCB Toronto won Agency of the Year – Strategy, globally.

“FCB’s performance at this year’s festival is a testament to the power of generosity. This generous spirit can be found in our clients, our partners and our people. Together, we all win,” said Susan Credle, FCB Global Chair & Global Chief Creative Officer. “The sustained success of the FCB network is only possible because of our collective commitment to Timeless & Timely creative ideas that drive business today while building brand equity for the future. It’s nice to see that commitment rewarded by our industry.”

The Titanium winner, “Dyslexic Thinking” from FCB Inferno for Virgin Group, in collaboration with LinkedIn and Made By Dyslexia, was awarded for the dedicated effort to making “Dyslexic Thinking” recognized as a celebrated term and valuable skill set. The idea got “Dyslexic Thinking” added as a skill on LinkedIn, the world’s largest professional network, offering its 810+ million members globally the option to add “Dyslexic Thinking” to their profile, with Dictionary.com also adding “Dyslexic Thinking” as an official term, noting its “strengths in creative, problem-solving and communication skills.”

Danilo Boer, FCB Global Creative Partner, said: “Working with Virgin, LinkedIn and Made By Dyslexia on ‘Dyslexic Thinking’ was truly inspiring. This idea not only fundamentally changed the perception of the word ‘dyslexia’ and created an entirely new term in the dictionary, but it started a seismic shift in making neurodiversity an asset that companies around the world need now more than ever.”

Additional highlights from the 2022 festival include:

• FCB Lisbon won Portugal’s first-ever Grand Prix (Design) for “Portuguese (Re)Constitution” for Penguin Books (Penguin Random House) — 30 years after CEO and Creative Director Edson Athayde brought a Gold Lion to the country for the first time.
• FCB Chicago, FCB New York and FCB Brasil collected 9 Lions across 4 campaigns for AB InBev, named 2022 Creative Marketer of the Year, including FCB New York’s “McEnroe vs. McEnroe,” FCB Chicago/FCB New York’s “Michelob ULTRA Courtside,” FCB New York/FCB Brasil’s “Mike’s in a Beer World” and FCB Chicago/FCB New York’s “Contract for Change,” which garnered the 2022 Creative Effectiveness Grand Prix, adding to the campaign’s 2021 Grand Prix (PR) and Titanium Lion accolades.
• FCB Canada collected Gold Lions in Creative Strategy and Creative Effectiveness for their work with the Canadian Down Syndrome Society and ultimately earned the title of Global Agency of the Year – Strategy.
• FCB Chicago and FCB India collaborated to earn 14 Lions, including 2 Gold Lions in the Media and Social/Influencer categories for “Chatpat” on behalf of SOS Children’s Villages India, and 1 Gold Lion in Direct for “The Nominate Me Selfie” on behalf of Political Shakti & The Times of India.

“Now more than ever, brands need to use creativity to drive exponential growth,” said Tyler Turnbull, FCB Global Chief Executive Officer. “Congratulations to everyone who helped our clients grow, thrive and be recognized as some of the most innovative in the world.”

In 2020/2021, Cannes Lions named FCB its Network of the Year for the first time in the network’s nearly 150-year-history. Since that milestone, FCB was featured on the 2022 Ad Age A-List and the 2022 Fast Company Most Innovative list and was named the #1 Global Network on The Good Report.

About FCB
FCB (Foote, Cone & Belding) is a global, award-winning and integrated marketing communications company with a heritage of creativity and success dating from 1873. Named 2022 Ad Age A-List, 2022 Fast Company Most Innovative, Cannes Lions 2020/2021 Global Creative Network of the Year, Adweek 2020 Global Agency of the Year and the #1 Global Network on The Good Report, FCB focuses on creating Never Finished campaign ideas that have the power to transform brands, businesses and communities. With more than 8,000 people in 109 operations in 80 countries, the company is part of the Interpublic Group of Companies (NYSE: IPG). Visit fcb.com or follow @FCBglobal on Instagram and Twitter and FCB Global on Facebook and LinkedIn.

Media Contact:
Titus Wouda Kuipers
+1 201-463-2858
titus.woudakuipers@fcb.com

CANNES, France, June 27, 2022 (GLOBE NEWSWIRE) — FCB Inferno London and Virgin Group, in collaboration with LinkedIn and Made By Dyslexia, have been awarded a Titanium Lion for their “Dyslexic Thinking” campaign at the Cannes Lions International Festival of Creativity — one of only six awarded in the category, FCB Inferno’s first-ever Titanium Lion and the network’s fourth in three consecutive years.

The Titanium category, the Festival’s most prized and hardest category to win, celebrates breakthrough ideas that are provocative and that point to a new direction in the industry. The accolade follows the campaign’s success in other categories this week: two Silvers — one in PR and one in Social & Influencer — and three Bronze Lions: in Brand Experience & Activation, Creative Strategy and PR.

The campaign, created by FCB Inferno London, got “Dyslexic Thinking” added as a skill on LinkedIn, the world’s largest professional network, offering its 810+ million members globally the option to add “Dyslexic Thinking” to their profile. Thanks to the initiative, Dictionary.com is also adding “Dyslexic Thinking” as an official term, noting its “strengths in creative, problem-solving and communication skills.” Most importantly, it created a seismic shift by making neurodiversity an asset that companies around the world seek out to better their business.

The agency’s success at this year’s Festival has helped make FCB Inferno the third most-awarded agency in the UK in 2022 — the third consecutive year FCB Inferno has earned top-three UK creative agency credit at the Festival.

Tamara Pickett, Virgin Group communications and external relations director, said: “As a company founded by one of the world’s most iconic entrepreneurs whose success has been fuelled by dyslexic thinking, Virgin was proud to partner on this important work. Sir Richard Branson now lists ‘Dyslexic Thinking’ as a skill on his LinkedIn profile, and we are thrilled to see it be honoured in such a meaningful way. We hope this is just the beginning of companies across the world helping to give a voice to the many diverse groups and attributes that give businesses a clear advantage.”

Kate Griggs, founder and CEO of Made By Dyslexia, said: “At Made By Dyslexia, our mission is to empower dyslexic thinking in every school and every workplace. By adding Dyslexic Thinking as a skill on LinkedIn, it immediately redefines it as the valuable asset that it is. I’m so proud and pleased that this campaign has been recognised for the systemic change that it will create.”

Owen Lee, chief creative officer at FCB Inferno London, said: “This campaign has been incredibly special for all of us that have had the honour of helping bring it to life and a real testament to the kind of ‘Never Finished’ ideas we aim to create. The real reward and credit though goes to all the people out there with dyslexia who have spent much of their lives trying to hide their neurodiversity.”

Katy Wright, managing director of FCB Inferno, said: “I have dyslexia and as a child I felt it was something I had to hide. But growing up I saw the positives and the ways it helped me to approach problem-solving differently. Dyslexia is not a superpower and it’s certainly not a disorder, it’s simply a different and creative way of thinking and it’s been so important for us to finally get that fact recognised. Winning this award means so much on a personal level. I hope our campaign inspires more employers to do everything possible to encourage all forms of diversity in the workplace.”

Danilo Boer, global creative partner at FCB Global, said: “Working with Virgin and LinkedIn on ‘Dyslexic Thinking’ was truly inspiring. This idea not only fundamentally changed the perception of the word ‘dyslexia’ and created an entirely new term in the dictionary, but it also started a seismic shift in making neurodiversity an asset that companies around the world need now more than ever.”

The agency’s success is another major win in what has been a big year for FCB Inferno, which added new leaders to its C-suite in 2021. Under this team, FCB Inferno launched new creative data practice FCB/SIX and has expanded its client base with new wins, including Unite Students, as well as organic growth from existing clients such as Kimberly-Clark and the UK Government. It also moved into new offices at the Old Bailey earlier this year, becoming the only creative agency embedded there with IPG’s media, data and audience offerings.

About FCB Inferno
FCB Inferno, based in London, is one of the world’s leading creative agencies and works with a diverse mix of local and global clients. The agency creates ideas that drive business today and build brands of tomorrow — ideas that endure and are Never Finished. Its work is highly commercial and purpose-driven for some of the world’s most iconic brands, including the acclaimed “This Girl Can” campaign for Sport England.

FCB Inferno’s creativity and effectiveness have been recognised at numerous global award shows for solving clients’ business problems in innovative ways. This includes multiple Grands Prix at Cannes, D&AD White and Yellow Pencils and even a BAFTA nomination.

The agency is part of the FCB Network with over 8,000 employees across 80 countries. FCB was named Global Agency Network of the Year by Adweek 2020 and Network of the Year at the Cannes International Festival of Creativity for 2020/2021. FCB was also awarded the inaugural One Show Fusion Pencil for diversity and inclusion, the Good Report’s #1 Campaign and Network, and a Grand Prix in e-commerce at Cannes.

About Virgin Group
The Virgin Group is a leading international investment group and one of the world’s most recognised and respected brands. Created in 1970 with the birth of Virgin Records, the Virgin Group has gone on to invest in, incubate, and grow a number of successful businesses in the private and public markets. The Virgin Group has expanded into many sectors since its inception, driven by Sir Richard’s ambition to create the world’s most irresistible brand. These sectors include travel & leisure, financial services, health & wellness, technology & internet-enabled, music & entertainment, media & mobile, space, and renewable energy. Find out more at virgin.com

About Made By Dyslexia
We’re a global charity, led by successful dyslexics. We’ve built the world’s largest community of dyslexic people and our allies. Our purpose is to help the world to understand, value and support dyslexia.

We believe in the game-changing power of Dyslexic Thinking. After all, everything from the light bulb to the iPhone, the aeroplane to the motor car, was invented by a dyslexic mind. And our skills are vital in shaping the future too.

Our mission is to train every teacher and workplace to spot, support and empower every dyslexic mind. This mission is aligned with the UN Sustainable Development Goals and we aim to achieve it by 2030.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a2f9479a-fcf2-4e5d-8bc9-155f36b35ac0

Media Contact:
Titus Wouda Kuipers
+1 201-463-2858
titus.woudakuipers@fcb.com